Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

97.54 +1.29 (+1.34%)

Streaming Delayed Price Updated: 12:16 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

70 71 Next >

Novavax Shares Jumped in January While Others Slipped

February 01, 2023

Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line.

Via MarketBeat

Why BioNTech And Moderna Shares Are Falling After Pfizer News ↗

January 31, 2023

BioNTech SE - ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday morning in sympathy with Pfizer Inc. (NYSE:

Via Benzinga

$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns ↗

January 30, 2023

The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths.

Via Benzinga

Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip ↗

January 27, 2023

The FDA's experts voted in favor of annual boosters on Thursday.

Via Investor's Business Daily

Mergers and Acquisitions in 2023 Off To A Strong Start

January 26, 2023

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Via MarketBeat

Analyst Ratings for BioNTech ↗

January 24, 2023

Via Benzinga

BioNTech Starts Dosing In Herpes Vaccine Candidate Study ↗

December 21, 2022

Via Benzinga

Thursday Predictions: 3 Hot Stocks for Tomorrow ↗

January 25, 2023

Airline stocks, credit card stocks, and vaccine stocks are our focus when it comes to the hot stocks for tomorrow. Here's why.

Via InvestorPlace

COVID-19 Vaccine Strategy Might Follow The Influenza Shot Way, FDA To Decide Today ↗

January 23, 2023

The FDA is considering a significant shift in the U.S.'s COVID-19 vaccine strategy to simplify vaccination against COVID-19.

Via Benzinga

Google Layoffs 12K Employees, Netflix's Q4 Earnings And CEO Steps Down, FDA Rejects Eli Lilly's Alzheimer's Candidate: Top Stories Friday, Jan. 20 ↗

January 20, 2023

Here's a round-up of stories from around the globe and from various media outlets. Benzinga

Via Benzinga

Israel Says No Stroke Risk Associated With Pfizer/BioNTech Updated COVID-19 Shots ↗

January 20, 2023

Israel health ministry official said Isreal had not identified any evidence linking strokes to an updated coronavirus vaccine by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX).

Via Benzinga

Pfizer (PFE) Stock Falls on Analyst Downgrade ↗

January 17, 2023

Although Pfizer led the charge in forwarding Covid-19 solutions, possibly waning relevancy poses serious concerns for PFE stock.

Via InvestorPlace

Pfizer Stock Dives As Analyst Calls For 'Covid Reset' And Downgrades Shares ↗

January 17, 2023

Shares have skidded almost 10% in the first two weeks of 2023.

Via Investor's Business Daily

US Health Agencies Investigate Preliminary COVID-19 Vaccine Safety Signal In Older People ↗

January 16, 2023

The U.S.

Via Benzinga

Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot ↗

January 13, 2023

Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand.

Via Benzinga

Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing” ↗

January 12, 2023

Small-cap speculative biotech stocks regain interest with volatility.

Via Talk Markets

BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British Startup ↗

January 10, 2023

Via Benzinga

BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

January 10, 2023

From BioNTech SE

Via GlobeNewswire

Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly ↗

January 09, 2023

Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) reduced hospitalizations among older patients.

Via Benzinga

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

2 Top Biotech Stocks to Buy Right Now ↗

January 06, 2023

These two pharmaceutical companies pay market-beating dividends to shareholders.

Via The Motley Fool

BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030

January 05, 2023

From BioNTech SE

Via GlobeNewswire

Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study ↗

January 03, 2023

Via Benzinga

Why BioNTech Was a Sickly Stock This Week ↗

December 30, 2022

The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks.

Via The Motley Fool

BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 28, 2022

From BioNTech SE

Via GlobeNewswire

Three Pharma Stocks to Sell Before They Die ↗

December 24, 2022

As we head into New Year 2023, these are just some of the top pharma stocks to sell at the start of January.

Via InvestorPlace

BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

December 23, 2022

From BioNTech SE

Via GlobeNewswire

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

December 22, 2022

From BioNTech SE

Via GlobeNewswire

Update on First BioNTainer for African-based mRNA Manufacturing Facility

December 21, 2022

From BioNTech SE

Via GlobeNewswire

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

December 21, 2022

From BioNTech SE

Via GlobeNewswire

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.